[Nucala ISS/SCS Committee. Last updated in June 2022.]
GSK call for research proposals of relevance to disease understanding and impact of mepolizumab in two disease areas:
• Severe eosinophilic asthma (SEA)
• Hypereosinophilic syndrome (HES)
Applications are invited in the following areas:
• Impact of mepolizumab on prevention of organ damage and disease progression
• Composite outcomes with real-world use of mepolizumab, such as remission
• Patient identification biomarkers of those at risk of worse long-term clinical outcomes
• Non-eosinophilic biological effects of interleukin 5 (IL-5)
• CNS assessment of mechanisms of mepolizumab in promoting “well-being”

[Daprodustat ISS/SCS Committee. Last updated in May 2022.]
• Clinical practices and behaviours related to the management of anemia of CKD
• Healthcare resource utilisation related to anemia of CKD
• Burden and impact of untreated anemia of CKD across different geographies or related to differential healthcare access, including underserved populations
• Novel technologies to improve patient care and/or the patient experience in the management of anemia of CKD
• Effectiveness of Daprodustat in subgroups of special interest
Including patients not reaching Hb target, inflamed patients, diabetic patients, anephritic patients, home dialysis, peritoneal dialysis, transplant
• New indications (other than anemia of CKD), where Daprodustat could benefit patients

[Otilimab ISS/SCS Committee. Last updated in Jan 2022.]
GSK is not accepting new supported study submissions related to otilimab COVID at this time. Any accepted submissions, where funding has been confirmed, will be progressed as planned. Please contact your local GSK office if you require further information. We will publish updates at this site shortly. Thank you.

[Belimumab ISS/SCS Committee. Last updated in May 2021.]
GSK is not accepting new supported study submissions related to Belimumab (Benlysta) at this time. Any accepted submissions, where funding has been confirmed, will be progressed as planned. Please contact your local GSK office if you require further information. We will publish updates at this site should things change. Thank you.